Citation Impact
Citing Papers
A Gene-Coexpression Network for Global Discovery of Conserved Genetic Modules
2003 StandoutScience
Removing T-cell epitopes with computational protein design
2014 StandoutNobel
A gene atlas of the mouse and human protein-encoding transcriptomes
2004 Standout
Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies
2013
A Recombinant Immunotoxin against the Tumor-Associated Antigen Mesothelin Reengineered for High Activity, Low Off-Target Toxicity, and Reduced Antigenicity
2012
An enzymatic toolkit for selective proteolysis, detection, and visualization of mucin-domain glycoproteins
2020 StandoutNobel
CD22: A Multifunctional Receptor That Regulates B Lymphocyte Survival and Signal Transduction
2005
Novel Markers of Pancreatic Adenocarcinoma in Fine-Needle Aspiration: Mesothelin and Prostate Stem Cell Antigen Labeling Increases Accuracy in Cytologically Borderline Cases
2003
Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting
1996
Pancreatic cancer
2004 Standout
Siglecs and their roles in the immune system
2007 Standout
Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors
2006
The history of cancer epigenetics
2004 Standout
Synthesis of Biomolecule‐Modified Mesoporous Silica Nanoparticles for Targeted Hydrophobic Drug Delivery to Cancer Cells
2011 StandoutNobel
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Caspases: pharmacological manipulation of cell death
2005 Standout
Functionalized Poly(ethylene glycols) for Preparation of Biologically Relevant Conjugates
1995
Gold nanoparticles in delivery applications☆
2008 Standout
Immunotoxins containing Pseudomonas exotoxin A: a short history
2003
Control of human mesothelin-expressing tumors by DNA vaccines
2007
Cancer Statistics, 2006
2006 Standout
Effect of pegylation on pharmaceuticals
2003 Standout
A review of stimuli-responsive nanocarriers for drug and gene delivery
2008 Standout
Overexpression of folate binding protein and mesothelin are associated with uterine serous carcinoma
2007
Nanocarriers as an emerging platform for cancer therapy
2007 Standout
Mono-N-terminal poly(ethylene glycol)–protein conjugates
2002
Immunotoxin therapy of cancer
2006
LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation
2021 StandoutNobel
Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays
2003
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Dendrimers in biomedical applications—reflections on the field
2005 Standout
Polymer conjugates as anticancer nanomedicines
2006 Standout
Removal of B cell epitopes as a practical approach for reducing the immunogenicity of foreign protein-based therapeutics☆
2009
Effects of cholesterol-tagged small interfering RNAs targeting 12/15-lipoxygenase on parameters of diabetic nephropathy in a mouse model of type 1 diabetes
2008
Short‐Course Raltegravir Intensification Does Not Reduce Persistent Low‐Level Viremia in Patients with HIV‐1 Suppression during Receipt of Combination Antiretroviral Therapy
2010
The development of immunoconjugates for targeted cancer therapy
2014
Radiolabelled lymphokines and growth factors for in vivo imaging of inflammation, infection and cancer
2003
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Mesothelin targeted cancer immunotherapy
2007
Strategies in the design of nanoparticles for therapeutic applications
2010 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
Site-specific PEGylation of a lysine-deficient TNF-α with full bioactivity
2003
Enzymatic procedure for site-specific pegylation of proteins
2002
Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir
2011 StandoutNobel
Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas
2003
Novel intravascular macromolecular MRI contrast agent with generation‐4 polyamidoamine dendrimer core: Accelerated renal excretion with coinjection of lysine
2001
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Antibody–cytotoxic agent conjugates for cancer therapy
2005
Highly Efficient Reprogramming to Pluripotency and Directed Differentiation of Human Cells with Synthetic Modified mRNA
2010 Standout
Cancer and the chemokine network
2004 Standout
Knocking down barriers: advances in siRNA delivery
2009 Standout
The detection, treatment, and biology of epithelial ovarian cancer
2010
Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities
2003
The Emerging Role of In Vitro-Transcribed mRNA in Adoptive T Cell Immunotherapy
2019 StandoutNobel
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis
1998
Advances in Malignant Mesothelioma
2005 Standout
The dawning era of polymer therapeutics
2003 Standout
Pancreatic cancer
2011 Standout
The Human Cancer Antigen Mesothelin Is More Efficiently Presented to the Mouse Immune System when Targeted to the DEC‐205/CD205 Receptor on Dendritic Cells
2009 StandoutNobel
Chimeric Receptor mRNA Transfection as a Tool to Generate Antineoplastic Lymphocytes
2009
A Caspase-6 and Anti-Human Epidermal Growth Factor Receptor-2 (HER2) Antibody Chimeric Molecule Suppresses the Growth of HER2-Overexpressing Tumors
2004
Hierarchical Assembly of Model Cell Surfaces: Synthesis of Mucin Mimetic Polymers and Their Display on Supported Bilayers
2007 StandoutNobel
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
2004 Standout
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins
2003
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
2001 Standout
Mechanised materials
2010 StandoutNobel
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
2005 Standout
Mesothelin
2004
Polymeric Systems for Controlled Drug Release
1999 Standout
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
2001
Hydrogels for Tissue Engineering
2001 Standout
Advances in targeted therapeutic agents
2010
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Mesothelin Expression in Human Lung Cancer
2007
Immunogenicity of therapeutic recombinant immunotoxins
2016
A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
2008
Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P
2009
Molecular classification of human carcinomas by use of gene expression signatures.
2001
Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates
2011
Identification of Novel Human CTL Epitopes and Their Agonist Epitopes of Mesothelin
2005
Chemoselective Approaches to Glycoprotein Assembly
2001 StandoutNobel
Isolation of a high-affinity stable single-chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity
1998
Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes
2012
Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin
1994
Chemistry of polyethylene glycol conjugates with biologically active molecules
1995
Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma
1999 Standout
CD22 Is a Recycling Receptor That Can Shuttle Cargo between the Cell Surface and Endosomal Compartments of B Cells
2010
Natural Products as Sources of New Drugs from 1981 to 2014
2016 Standout
Site-Specific Attachment of Functionalized Poly(ethylene glycol) to the Amino Terminus of Proteins
1996
Functionalization of Tumor Necrosis Factor-α Using Phage Display Technique and PEGylation Improves Its Antitumor Therapeutic Window
2004
Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes
2011
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
A cell nanoinjector based on carbon nanotubes
2007 StandoutNobel
Phase I Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With B-Cell Malignancies
2005
Synthesis of Lipidated Green Fluorescent Protein and Its Incorporation in Supported Lipid Bilayers
2005 StandoutNobel
In vivo targeting of B-cell lymphoma with glycan ligands of CD22
2010
Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes
2014 StandoutNobel
Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
2011
Works of Qingcheng Wang being referenced
Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys
1999
Genetic Engineering of Glomerular Sclerosis in the Mouse via Control of Onset and Severity of Podocyte-Specific Injury
2005
Anti-Tumor Activity of K1-LysPE38QQR, an Immunotoxin Targeting Mesothelin, a Cell-Surface Antigen Overexpressed in Ovarian Cancer and Malignant Mesothelioma
2000
Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.
2000
Aminosyn II effectively blocks renal uptake of 18F-labeled anti-tac disulfide-stabilized Fv.
1998
An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes
2008
In Vitroandin VivoCytotoxic Activities of Recombinant Immunotoxin 8H9(Fv)-PE38 against Breast Cancer, Osteosarcoma, and Neuroblastoma
2004
Anti-HIV-1 immunotoxin 3B3(Fv)-PE38: enhanced potency against clinical isolates in human PBMCs and macrophages, and negligible hepatotoxicity in macaques
2006
Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
1994
Inhibition of TNF-α Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2
2000
Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner.
1994
Humoral Immune Response to Mesothelin in Mesothelioma and Ovarian Cancer Patients
2005